Mendis G P, Gibberd F B, Hunt H A
Seizure. 1993 Dec;2(4):319-23. doi: 10.1016/s1059-1311(05)80149-9.
The object of the study was to discover the changes in the plasma activities of hepatic enzymes in patients on anticonvulsant drugs. The plasma activities of aspartate transaminase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT) and glutamyltransferase (GGT) were studied in 123 unselected patients on anticonvulsants. The results were compared with 123 control patients not on anticonvulsants matched for age and sex. Patients with known liver disease were excluded. The plasma activities of AST and ALP were similar in the two groups. ALT and GGT were raised in patients on anticonvulsants. No patient developed clinical evidence of liver disease. It was concluded that raised ALT and GGT are not in themselves indications to alter anticonvulsant therapy. Changes in AST and ALP would be more specific markers of liver dysfunction in patients on anticonvulsants.
该研究的目的是发现服用抗惊厥药物患者的血浆肝酶活性变化。对123例未经过挑选的服用抗惊厥药物的患者,研究了其血浆中天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、丙氨酸转氨酶(ALT)和谷氨酰转移酶(GGT)的活性。将结果与123例年龄和性别相匹配的未服用抗惊厥药物的对照患者进行比较。排除已知患有肝病的患者。两组患者的AST和ALP血浆活性相似。服用抗惊厥药物的患者ALT和GGT升高。没有患者出现肝病的临床证据。得出的结论是,ALT和GGT升高本身并非改变抗惊厥治疗的指征。AST和ALP的变化可能是服用抗惊厥药物患者肝功能障碍更具特异性的标志物。